Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $55,647 - $66,985
-250 Reduced 3.88%
6,190 $1.6 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $63,325 - $71,472
250 Added 4.04%
6,440 $1.66 Million
Q3 2022

Nov 09, 2022

BUY
$194.69 - $268.46 $162,566 - $224,164
835 Added 15.59%
6,190 $1.65 Million
Q1 2022

May 12, 2022

SELL
$193.77 - $244.14 $125,950 - $158,691
-650 Reduced 10.82%
5,355 $1.13 Million
Q4 2021

Feb 10, 2022

SELL
$223.92 - $287.77 $67,176 - $86,331
-300 Reduced 4.76%
6,005 $1.44 Million
Q2 2021

Aug 09, 2021

SELL
$259.0 - $414.71 $747,733 - $1.2 Million
-2,887 Reduced 31.41%
6,305 $2.18 Million
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $1.96 Million - $2.3 Million
-8,081 Reduced 46.78%
9,192 $2.57 Million
Q3 2020

Nov 13, 2020

SELL
$264.77 - $305.71 $807,548 - $932,415
-3,050 Reduced 15.01%
17,273 $4.9 Million
Q2 2020

Aug 11, 2020

BUY
$258.66 - $342.55 $3,879 - $5,138
15 Added 0.07%
20,323 $5.44 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $454,356 - $576,357
-1,690 Reduced 7.68%
20,308 $6.43 Million
Q4 2019

Feb 13, 2020

SELL
$220.06 - $304.07 $473,129 - $653,750
-2,150 Reduced 8.9%
21,998 $6.53 Million
Q3 2019

Nov 12, 2019

BUY
$217.44 - $243.88 $53,272 - $59,750
245 Added 1.02%
24,148 $5.62 Million
Q1 2019

May 09, 2019

SELL
$216.71 - $338.96 $3,250 - $5,084
-15 Reduced 0.06%
23,903 $5.65 Million
Q4 2018

Feb 07, 2019

BUY
$278.5 - $352.75 $2.35 Million - $2.97 Million
8,433 Added 54.46%
23,918 $7.2 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $102,728 - $134,340
350 Added 2.31%
15,485 $5.47 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $93,994 - $112,022
365 Added 2.47%
15,135 $4.39 Million
Q4 2017

Feb 08, 2018

SELL
$307.64 - $344.58 $83,062 - $93,036
-270 Reduced 1.8%
14,770 $4.71 Million
Q2 2017

Aug 18, 2017

BUY
N/A
15,040
15,040 $4.08 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $24.8B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Oak Associates LTD Portfolio

Follow Oak Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oak Associates LTD , based on Form 13F filings with the SEC.

News

Stay updated on Oak Associates LTD with notifications on news.